A Randomised Double-blind (Sponsor Open), Placebo Controlled, Single Ascending Dose, First Time in Human Study in Participants With Mild to Moderate Asthma to Assess Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of GSK3511294 Administered Subcutaneously
Phase of Trial: Phase I
Latest Information Update: 14 Jun 2018
At a glance
- Drugs GSK-3511294 (Primary)
- Indications Asthma
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline
- 15 Feb 2018 Planned primary completion date changed from 6 Dec 2018 to 24 Sep 2019.
- 31 Jan 2018 Planned End Date changed from 24 Jul 2019 to 24 Sep 2019.
- 25 Jan 2018 Planned End Date changed from 24 Jan 2019 to 24 Jul 2019.